Evaluation of the protective effect of N-acetylcysteine on contrast media nephropathy

Aiyoub Pezeshgi1,2, Negin Parsamanesh2, Goodarz Farhood2, Khalil Mahmoodi1*

1Zanjan Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
2Department of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

ARTICLE INFO

Article Type: Original

Article History:
Received: 3 June 2014
Accepted: 25 June 2014
Published online: 1 September 2015

Keywords:
Contrast induced nephropathy
Acute kidney injury
Contrast agents

ABSTRACT

Introduction: Intravenous contrast agents can cause acute decline in kidney function, especially in patients with risk factors.

Objectives: In this study, we aimed to examine the ameliorative effect N-acetylcysteine (NAC) to reduce the incidence of contrast nephropathy.

Patients and Methods: This study was a prospective, randomized, double-blind clinical trial on 150 patients who underwent coronary angiography. The study was carried out on patients undergoing coronary angiography. Patients were randomly assigned into 2 groups of intervention group and control subjects. Intervention group took NAC 600 mg orally twice a day. It was administered one day before angiography and continued until the second day after angiography. Serum creatinine was measured before and three days after coronary angiography.

Results: There was no significant difference between intervention and control groups at baseline (P > 0.05). However, there was a significant decline in creatinine level among NAC patients (P = 0.001). Saline group had significantly higher proportion of nephropathy cases than NAC patients

Conclusion: We found that the consumption of NAC is useful for contrast induced nephropathy (CIN) prevention.

Implication for health policy/practice/research/medical education:
In a prospective, randomized, double-blind clinical trial on 150 patients who underwent coronary angiography, we found that the use of N-acetylcysteine (NAC) is useful for contrast induced nephropathy (CIN) prevention.

Please cite this paper as: Pezeshgi A, Parsamanesh N, Farhood G, Mahmoodi K. Evaluation of the protective effect of N-acetylcysteine on contrast media nephropathy. J Renal Inj Prev. 2015;4(4):109-112. DOI: 10.12861/jrip.2015.23

Introduction
Intravenous contrast agents can cause the acute decline in kidney function, especially in patients with risk factors (1). Contrast induced nephropathy (CIN) is the third most common cause of inpatient acute kidney injury (AKI) (2-4). CIN occurs 2 to 3 days after intravascular administration of iodinated contrast material. CIN is defined as the presence of 0.5 mg/dl creatinine or more than 25% rise in baseline creatinine during 48 hours after receiving the contrast agent (3,4). Serum creatinine usually reach to peak on the third to fifth day of administration and returns to the initial value on the seventh day. It is asymptomatic and non-oliguric, except in some cases in which the peak of creatinine is observed between fifth and tenth days, which returns to baseline on the second to third weeks (6). In rare cases of CIN, patients may require replacement therapy. CIN increases mortality and morbidity rate in the first year, especially when the patient needs replacement therapy (7). It have always been assumed that the risk of CIN can be reduced via using preventive methods such as full hydration by intravenous saline or oral fluid intake, sodium bicarbonate, vasodilators, various diuretics (furosemide or mannitol), calcium channel blockers, dopamine, theophylline, N-acetylcysteine (NAC), vitamins E and C, and also hemodiafiltration (8-15). Most patients who undergo coronary angiography areelderly
patients with risk factors such as diabetes, hypertension, congestive heart failure, and chronic kidney disease, which predispose them to CIN. In most cases, appropriate hydration is not performed to deal with the underlying disease of such patients (16).

Objectives
In this study, we aimed to examine the ameliorative effect of NAC to reduce the incidence of contrast nephropathy.

Patients and Methods
Our study was a prospective, randomized, double-blind clinical trial. The study was carried out on patients undergoing coronary angiography in Ayatollah-Mousavi hospital, Zanjan, in 2012. Patients were randomly assigned into 2 groups of NAC and control subjects. They were randomly divided into 2 groups. The control group received normal saline only and the case group received normal saline and oral NAC 600 mg twice daily. Information on age, gender, history of diseases and medications were recorded. Both groups were hydrated with saline. Case group took NAC 600 mg orally twice a day. It was administered one day before angiography and continued until the second day after angiography. Serum creatinine was measured before and three days after coronary angiography. Researchers and patients were blind to patients’ groups. All patients received a unique brand and a fixed dose of low-osmolar contrast media. The patients continued to take their previously used medications. During the first three days we excluded patients who had a change in their medications or their mean arterial blood pressure when became less than 85 mm Hg.

Ethical issues
The research followed the tenets of the Declaration of Helsinki. Informed consent was obtained. The research was approved by the Ethics Committee of Zanjan Medical University.

Data analysis
Statistical analysis was performed using SPSS version 15 (SPSS Inc., Chicago, IL) software package. Descriptive statistics were used to summarize the data. Fisher exact test, chi-square test, t test and analysis of variance (ANOVA) were used. A P<0.05 was considered significant.

Results
Out of a total of 150 patients who were enrolled in the study, 83 patients were female and 67 patients were male. They was 75 peoples in each group. Table 1 shows mean creatinine level based on related variables in intervention and control groups at baseline. There was no significant difference of serum creatinine between intervention and control groups at base line (P>0.05; Table 1).

Mean creatinine level at the end of the study in intervention and control groups is shown in Table 2. For either the 2 groups, males experienced a higher reduction of creatinine level. Regardless of the history of hypertension, diabetes, angiotensin II receptor blockers (ARBs), or angiotensin-converting enzyme (ACE) inhibitor drugs, the mean level of creatinine was declined in the intervention group than control group, though the difference was not significant. However, there was a significant decline in creatinine level from base among NAC patients (P=0.001; Table 2). Table 3 shows the frequency of nephropathy cases among the studied groups who had a history of taking ARB or ACE drugs. Neither NAC nor saline group who had a history of administration of ARB showed signs of nephropathy (P>0.5). However, there was a significant higher proportion of nephropathy cases in saline group (P=0.001; Table 3).

Table 4 shows univariate analysis of variance of some variables and their main effects on serum creatinine level at the end of study. As shown, NAC participants experienced significantly higher decline in creatinine level (P=0.001; Table 4).

Discussion
Several clinical trial and meta-analysis have approved or rejected the effect of NAC on intravenous contrast material-induced nephropathy. In 2004 Bagshaw et al (9), published

Table 1. Mean serum creatinine level by study group at baseline

| Variable              | Saline normal (n = 75) Mean ± SD | NAC (n = 75) Mean ± SD | Total (n = 150) Mean ± SD | P value |
|-----------------------|----------------------------------|------------------------|---------------------------|---------|
| Gender                | 1.17±0.40 (n = 83)               | 1.17±0.39              | 1.17±0.39                 | 0.064   |
|                       | 1.25±0.26 (n = 67)               | 1.31±0.31              | 1.28±0.39                 |         |
| Hypertension          | 1.29±0.38 (n = 107)              | 1.22±0.35              | 1.25±0.36                 | 0.074   |
|                       | 1.05±0.20 (n = 43)               | 1.27±0.42              | 1.13±0.31                 |         |
| Diabetes mellitus     | 1.21±0.35 (n = 109)              | 1.17±0.35              | 1.19±0.35                 | 0.151   |
|                       | 1.20±0.31 (n = 41)               | 1.33±0.37              | 1.28±0.35                 |         |
| ARB receivers         | 1.37±0.18 (n = 15)               | 1.28±0.39              | 1.30±0.35                 | 0.32    |
|                       | 1.20±0.35 (n = 135)              | 1.22±0.36              | 1.21±0.35                 |         |
| ACE receivers         | 1.19±0.25 (n = 79)               | 1.22±0.34              | 1.20±0.29                 | 0.613   |
|                       | 1.23±0.48 (n = 71)               | 1.23±0.38              | 1.23±0.49                 |         |
| Mean                  | 1.20±0.34                       | 1.23±0.36              | -                         | 0.71    |

110 Journal of Renal Injury Prevention, Volume 4, Number 4, December 2015 http://journalrip.com
N-acetylcysteine and contrast nephropathy

A meta-analysis, which covered 1261 patients in 14 studies. Only in 5 studies the incidence of CIN was lower after administration of NAC. Other studies showed no effect. In general, they did not express any related finding (9). In 2005 van den Berk et al (17), published a meta-analysis in Amsterdam, Netherlands. In their study, 5 out of the 16 studies showed the significant effects of NAC. In another study, the protective effect of NAC with a dose of 1200 mg twice daily was more than that with a dose of 600 mg (18). In 2004, Liu et al conducted a meta-analysis study at the University of California from 1974 to 2004, which included 9 randomized controlled trials (RCTs). He concluded that NAC was effective for the prevention of CIN because it was low-risk and low cost, and was advisable to use (19). Likewise, in 2007 Gonzales et al (20), conducted a meta-analysis which included 22 studies with 2746 patients, however the results did not support our idea. Acetylcysteine for contrast-induced nephropathy Trial (ACT), is the largest RCT. During 2008 and 2009 a study was conducted in 35 centers in Brazil, and 2300 high-risk patients were evaluated for CIN and underwent coronary angiography. The patients who received 1200 mg of oral NAC were compared with the placebo group. Of all, 13% of patients had heart failure and 18% had the renal failure (serum creatinine more than 1.5 mg/dl). It showed the reduction of the incidence of CIN (10). Additionally in a meta-analysis by Kwok et al (12), which included seven and nine RCT systematic reviews (15976 patients), a significant reduction of CIN risk was reported by administration of NAC, which supported its protective effect. In our study, after oral administration of NAC, mean serum creatinine did not increase three days after receiving the contrast, and rather it decreased. The frequency of contrast nephropathy in patients receiving NAC is lower. Thus the protective effect was achieved.

Conclusion
We found that the administration of NAC is useful for CIN prevention.

Limitations of the study
We lost a number of patients because they refused to

Table 2. Mean serum creatinine level by study group at the end of intervention

| Variable          | Group                  | Saline normal n=75 Mean ± SD | NAC n=75 Mean ± SD | total n=150 Mean ± SD | P value |
|-------------------|------------------------|------------------------------|--------------------|-----------------------|---------|
| Gender            | Female (n=83)          | 1.30±0.50                    | 1.07±0.38          | 1.18±0.45             | 0.14    |
|                   | Male (n=67)            | 1.36±0.30                    | 1.17±0.31          | 1.27±0.32             |         |
| Hypertension      | More than 140 mm Hg (n=107) | 1.42±0.47                | 1.10±0.33          | 1.24±0.43             | 0.27    |
|                   | Lower than 139 (n=43)  | 1.17±0.21                    | 1.14±0.44          | 1.16±0.31             |         |
| Diabetes mellitus | Yes (n=109)            | 1.34±0.44                    | 1.08±0.34          | 1.22±0.42             | 0.91    |
|                   | No (n=41)              | 1.30±0.30                    | 1.17±0.36          | 1.21±0.35             |         |
| ARB receivers     | Yes (n=15)             | 1.35±0.12                    | 1.12±0.38          | 1.18±0.34             | 0.71    |
|                   | No (n=135)             | 1.33±0.42                    | 1.11±0.35          | 1.22±0.40             |         |
| ACE receivers     | Yes (n=79)             | 1.31±0.27                    | 1.14±0.35          | 1.25±0.31             | 0.33    |
|                   | No (n=71)              | 1.36±0.62                    | 1.09±0.36          | 1.19±0.48             |         |
| Mean              | 1.33±0.41              | 1.11±0.35                    |                   | -                     | 0.001   |

Table 3. Comparison of nephropathy frequency in the studied groups by ACE and ARB prescription

| Group                        | Nephropathy | p value |
|------------------------------|-------------|---------|
|                              | Yes n=14    | No n=136|
| Normal saline receivers      |             |         |
| ACE                          | 8           | 42      | 0.44   |
| No (n=25)                    | 5           | 20      |        |
| Yes (n=4)                    | 0           | 4       | 0.45   |
| No (n=71)                    | 13          | 58      |         |
| NAC receivers                |             |         |
| ACE receivers                | 0           | 29      | 0.61   |
| Yes (n=29)                   | 1           | 45      |        |
| No (n=46)                    | 0           | 11      | 0.85   |
| ARB receivers                | 1           | 63      |         |
| Yes (n=11)                   |             |         |
| No (n=64)                    |             |         |
| Total                        | 13          | 62      | 0.001  |
| Saline normal (n=75)         | 1           | 74      |         |
| NAC receivers (n=75)         |             |         |

Table 4. Analysis of the variables associated with serum creatinine level at the end of study

| Variable                      | P value |
|-------------------------------|---------|
| Gender (Female versus Male)   | 0.29    |
| Hypertension                  | 0.13    |
| Diabetes mellitus             | 0.85    |
| ARB receivers                 | 0.99    |
| ACE receivers                 | 0.90    |
| Group (NAC versus normal saline) | 0.001  |
continue the study or did not refer three days after taking contrast media. In addition, many of the patients were living in far distances, and we did not plan to take samples at their location. Hence, our conclusion was limited to a small number of patients.

**Authors’ contribution**
AP and NP conducted the research and prepared the primary draft. GF and KM revised the manuscript. AP further edited the paper. All authors read and signed the paper.

**Conflicts of Interest**
The authors declared no competing interests.

**Ethical considerations**
Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

**Funding/support**
This study was supported by a grant from Zanjan Medical University (Grant No. 19/3-3/2377).

**References**
1. Lameire N, van Biesen W, van holder R. Acute renal failure. Lancet. 2005;365:417-30.
2. Nash K, Hafeez A, Hou S. Hospital acquired renal insufficiency. AM J Kidney Dis. 2002;39:930-6.
3. Morcos SK, Thomsen HS. European society of urogenital radiology guidelines on administering contrast media. Abdom Imaging. 2003;28:187-90.
4. Wog GT, Irwin MG. Contrast induced nephropathy. Br J Anaesth. 2007;99:474-83.
5. Fishbani S, Durham JH, Marzo K, Rudnick M. N-acetylcysteine in the prevention of radiocontrast induced nephropathy. J Am Soc Nephrol. 2004;15:251-60.
6. Gleeson TG, Bulughapitya S Contrast induced nephropathy. AJR Am J Roentgenol. 2004;183:1673-89.
7. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast−induced nephropathy in patient with chronic kidney disease undergoing computed tomography: a double-blind comparison of ioxidanol and iopamidol. Invest Radiol. 2006;41:815-21.
8. Sandilands EA, Cameron S, Paterson F, Donaldson S, Briody L, Crowe J, et al. Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol. BMC Clin Pharmacol. 2012;12:3.
9. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2:38.
10. Berwanger O, Cavalcanti AB, Sousa AG, Buehler AM, Kodama AA, Carballo MT, et al. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation. 2011;124:1250-9.
11. Aitio ML. N-acetylcysteine – passe-partout or much ado about nothing? Br J Clin Pharmacol. 2006; 61:5-15.
12. Kwok CS, Pang CL, Yeong JK, Loke YK. Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol. 2013;86:20120272.
13. Dussol B, Moreau S, Lououdon A, Augure P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in choronic renal failure patients. Nephrol Dial Transplant. 2006;21;2120-26.
14. Briguori C, Airoldi F, D’Andrea D, Bonizzi E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115;1211-7.
15. Kalonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophline does prevent renal dysfunction include by radiographic contrast agents. J Nephrol. 1998;11:151-6.
16. Taliercio CP, Viestra RE, Fisher LD, Burnett JC. Risks of renal dysfunction with cardiac angiography. Ann Intern Med. 1986;104:501-504.
17. van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ. Bench-to-bedside review: Preventive measures for contrast-induced nephropathy in critically ill patients. Crit Care. 2005;9:361-70.
18. Thomson VS, Narayanan K, Singh JC. Contrast induced nephropathy in urology. Indian J Urol. 2009;25:437-45.
19. Liu R, Nair D, Ix J, Moore DH, Bent S. N-Acetylcysteine for the prevention of contrast-induced nephropathy; a systematic review and meta-analysis. J Gen Intern Med. 2005;20:193-200.
20. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Siewing PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;14:5-32.